Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-HCC: Atezolizumab + Bevacizumab vs TACE in Intermediate-stage HCC
NCT04803994Phase 3Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jul 2021
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Time to Failure of Treatment Strategy at 48 months. Started Jul 2021; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04803994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803994.